中生联合(03332)发布截至2025年6月30日止六个月的中期业绩，收益3.32亿元(人民币，下同)，同比减 少10.22%;股东应占溢利1532.2万元，同比减少54.14%;每股基本盈利1.62分。 ...

智通财经APP讯，中生联合(03332)发布截至2025年6月30日止六个月的中期业绩，收益3.32亿元(人民 币，下同)，同比减少10.22%;股东应占溢利1532.2万元，同比减少54.14%;每股基本盈利1.62分。 ...

格隆汇8月22日丨中生联合(03332.HK)发布公告，2025年上半年，收益减少约10.2%至约人民币3.32亿 元；毛利减少约9.4%至约人民币2.43亿元；母公司拥有人应占溢利约为人民币1532.2万元，同比减少 54.1%，每股基本盈利约为人民币1.62分。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 NANJING SINOLIFE UNITED COMPANY LIMITED* 南京中生聯合股份有限公司 截 至2025年6月30日 止 六 個 月 的 中 期 業 績 公 告 2025年 上 半 年 財 務 摘 要 中 期 業 績 南 京 中 生 聯 合 股 份 有 限 公 司（「本 公 司」）董 事（「董 事」）會（「董 事 會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（「本 集 團」）截 至2025年6月30日 止 六 個 月（「報 告 期 間」） 的 未 經 審 核 簡 明 綜 合 中 期 業 績 連 同2024年 同 期 的 比 較 數 字 如 下： * 僅 供 識 別 – 1 – • 收 益 減 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 NANJING SINOLIFE UNITED COMPANY LIMITED* 南 京 中 生 聯 合 股 份 有 限 公 司 南京中生聯合股份有限公司 董事長 桂平湖 中華人民共和國，南京，二零二五年八月十二日 於本公告日期，本公司執行董事為桂平湖先生、張源女士及朱飛飛女士；以及本 公司獨立非執行董事為余波先生、葉邦銀先生及程建明先生。 * 僅供識別 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3332） 董事會會議召開日期 南京中生聯合股份有限公司（「本公司」）董事會（「董事會」）兹通告謹定於二零二五 年八月二十二日（ 星期五 ）舉行董事會會議，以考慮及通過本公司及其附屬公司截 至二零二五年六月三十日止的六個月中期業績，及派發中期股息（ 如有 ），以及處 理其他事項。 承董事會命 ...

截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 南京中生聯合股份有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03332 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 946,298,370 | RMB | | 0.1 RMB | | 94,629,837 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 946,298,370 | RMB | | 0.1 RMB | | 94,629,837 | 本月底法定/註冊股本總額： RMB 94,629,837 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF3 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 NANJING SINOLIFE UNITED COMPANY LIMITED* 南 京 中 生 聯 合 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3332） 盈利警告 本 公 告 乃 由 南 京 中 生 聯 合 股 份 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法 例第571章證券及期貨條例第XIVA部之內幕消息條文（ 定義見上市規則 ）刊發。 * 僅供識別 – 1 – 潛在投資者及股東在買賣本公司證券時務請審慎行事。 承董事會命 南京中生聯合股份有限公司 桂平湖 董事長 中華人民共和國，南京，2025年7月30日 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投 ...

Group 1 - The A-share IP concept sector is experiencing a surge in popularity, with stocks like Aoya Co., Ltd. and Deyi Cultural Creativity reaching their daily limit up [1] - Bubble Mart's stock price continues to rise, reaching 277.6 HKD per share, with a market capitalization exceeding 370 billion HKD and a year-to-date increase of over 200% [1] - Suzhou Longjie has seen its stock price hit a daily limit for three consecutive days, reaching 21.54 CNY per share, with a total market value of 4.646 billion CNY [1] Group 2 - Suzhou Longjie's products include differentiated polyester filament and PTT fiber, primarily used in civilian textiles, with a projected revenue of 1.259 billion CNY in 2024, reflecting a year-on-year growth of 15.22% [3] - The net profit for Suzhou Longjie is expected to reach 58.14 million CNY in 2024, a significant increase of 520.05% year-on-year [3] - However, the company's performance in Q1 2025 showed a substantial decline, with a non-recurring net profit of only 680,000 CNY, down 93.01% year-on-year, indicating potential uncertainties in its development [3] Group 3 - The IP economy is currently experiencing explosive growth, with top IPs generating significant value across various sectors, including film, toys, and cultural products [3] - Bubble Mart's IP Labubu has seen sales reach 3.04 billion CNY in 2024, a year-on-year increase of over 700%, contributing to the company's stock price surge [4] - The Labubu series is in high demand globally, with products in the European and American markets selling at a premium of over seven times [5] Group 4 - Companies are increasingly collaborating with popular IPs to leverage their popularity for business expansion and performance growth, leading to a market frenzy for related concept stocks [5] - Long-term development for Suzhou Longjie relies on technological innovation and business expansion, with potential for performance growth if it successfully enters the IP derivative supply chain [5]

Summary of Key Points Core Viewpoint - As of May 6, a total of 55 stocks reached their 52-week highs, with notable performers including Shandong Molong (00568), Tokyo Central Auction (01939), and Andeli Juice (02218) showing significant increases in their high rates [1]. 52-Week Highs - Shandong Molong (00568) achieved a closing price of 5.020 with a peak of 5.250, marking a high rate of 185.33% - Tokyo Central Auction (01939) closed at 0.980, reaching a high of 3.180, resulting in a high rate of 112.00% - Andeli Juice (02218) closed at 16.000 with a peak of 23.950, reflecting a high rate of 87.11% - Other notable stocks include: - Crown Holdings (01872) with a high rate of 32.00% - Wutong International (00613) at 30.00% - Yao Cai Securities Financial (01428) at 10.47% [1]. 52-Week Lows - Madison Holdings (08057) recorded a closing price of 0.053, with a low of 0.050, reflecting a decline of 26.47% - China Classic Group (08281) closed at 0.060, reaching a low of 0.051, indicating a drop of 15.00% - Other companies experiencing significant declines include: - Zhongsheng United (03332) with a decline of 6.02% - Dingyi Group Investment (00508) at -5.88% - Derivative Group (06893) at -4.62% [2].

Financial Performance - Revenue increased by approximately 32.6% to RMB747.9 million (2023: RMB564.0 million) [21] - Gross profit increased by approximately 41.8% to RMB538.3 million (2023: RMB379.7 million) [21] - Profit for the Year was RMB34.6 million (2023: Profit of RMB52.6 million) [21] - Profit per share was RMB3.65 cents (2023: Profit per share RMB5.56 cents) [21] - The Group recorded a profit of approximately RMB 34.6 million for 2024, a decrease of approximately RMB 18.0 million from a profit of approximately RMB 52.6 million in 2023[46] - The gross profit increased by approximately 41.8% from approximately RMB 379.7 million in 2023 to approximately RMB 538.3 million in 2024, with a gross profit margin rising from 67.3% to 72.0%[53][57] - The Group recorded a foreign exchange loss of approximately RMB 18.5 million in 2024, compared to a gain of approximately RMB 1.7 million in 2023[63] - The effective tax rate increased from 9.5% in 2023 to 15.4% in 2024, primarily due to increased profits from one of the Group's subsidiaries[61][66] - The Group reported accumulated losses of RMB 284.5 million as of December 31, 2024[172] Dividends - The Board does not recommend the payment of any final dividend or special dividend for the Year (2023: Nil) [21] - The Group did not declare any final or special dividends for the year ended December 31, 2024[163] Market Strategy and Growth - The Company plans to expand its market presence and invest in new product development [22] - The Company is focusing on strategic acquisitions to enhance its competitive position [22] - The management anticipates continued growth in revenue and profitability in the upcoming fiscal year [22] - The focus on cross-border e-commerce for nutritional supplements under the Good Health brand contributed to rapid business growth[46] - The Group aims to achieve the goal of being the top seller in core product categories on e-commerce platforms[35] - The Group will expand its health products in multiple sales channels in the PRC, New Zealand, and Australia[32] - The Chinese consumer healthcare industry is experiencing high-quality and rapid development, driven by increasing health awareness among the large population[28] - The demand for high-quality imported healthcare products is growing, supported by the development of cross-border e-commerce platforms[28] - The younger generation's focus on appearance and healthy lifestyles is shifting market demand towards innovation and sustainability[31] Expenses and Cost Management - Selling and distribution expenses increased by approximately 63.4% from approximately RMB 250.0 million in 2023 to approximately RMB 408.6 million in 2024, representing 44.3% and 54.6% of the Group's revenue respectively[59][64] - Administrative expenses rose by approximately 22.7% from approximately RMB 72.2 million in 2023 to approximately RMB 88.6 million in 2024, accounting for 12.8% and 11.8% of revenue respectively[60][65] - The Group is committed to optimizing marketing and promotional expenses to improve overall profitability[35] Product Development - The Group launched a total of 26 new products in 2024, including 3 New Goodhealth series products and 22 Good Health series products[48][50] - The increase in revenue was primarily driven by significant growth in the Good Health brand's revenue from cross-border e-commerce platforms[52][56] - The nutritional supplements industry is characterized by rapid changes in demand for new products, necessitating constant innovation[89] Employee and Management Information - The Group employed 477 employees as of December 31, 2024, an increase from 349 employees as of December 31, 2023[90] - Total salaries and related costs for the year amounted to approximately RMB 120.8 million, up from approximately RMB 89.8 million in the previous year[90] - The Company has established various social security funds for its employees in the PRC, including pension and medical insurance[158] - The Company has appointed Mr. Ye Bangyin and Mr. Cheng Jianming as independent non-executive Directors effective from 23 October 2024[180] - Ms. Cai Tianchen and Mr. Wang Wei resigned as independent non-executive Directors effective from 22 October 2024 after serving for six years[180] Risk Factors - The Group faces risks related to the increase in prices of raw materials and packaging materials, which could adversely affect its business operations[82] - The Group is exposed to foreign currency risk primarily for purchases in USD, AUD, and NZD, which could significantly impact profitability due to fluctuations in exchange rates[89] - A depreciation of RMB could increase costs for purchasing products from Australia and New Zealand, requiring more RMB to obtain the equivalent foreign currency[89] - The Group has not used any derivative contracts to hedge against foreign currency risk, leaving it vulnerable to exchange rate fluctuations[89] - The success of new product offerings depends on accurately anticipating customer needs and timely commercialization[89] - Failure to introduce new products in a timely manner could lead to obsolescence and negatively affect operating results[89] - The Group's ability to maintain customer relationships and market share is contingent on its responsiveness to changing consumer preferences[89] Corporate Governance - The Company aims to ensure compliance with corporate governance practices as prescribed in the Listing Rules[145] - The Company has established four Board committees: Audit Committee, Remuneration Committee, Nomination Committee, and Strategy and Development Committee[145] - The Audit Committee assists the Board in reviewing financial information, risk management, and internal control systems[149] - The Remuneration Committee reviews and makes recommendations on the remuneration packages of individual Directors and senior management[150] - The Nomination Committee assesses the independence of independent non-executive Directors and makes recommendations on appointments[151] - The Strategy and Development Committee conducts research and submits proposals concerning long-term development strategies[152] Financial Position - Cash and cash equivalents decreased by approximately RMB 13.0 million during the year, with net cash inflow from operating activities of approximately RMB 1.0 million and net cash outflow from investing and financing activities of approximately RMB 6.0 million and RMB 4.5 million, respectively[69] - Inventories increased by approximately 9.4% to RMB 119.1 million as of December 31, 2024, compared to RMB 108.9 million in 2023, with inventory turnover days increasing by 15 days to approximately 196 days[70] - Trade receivables rose by approximately RMB 9.4 million or 28.9% to RMB 41.9 million as of December 31, 2024, driven by increased revenue from e-commerce channels[71] - Trade payables decreased by approximately RMB 20.3 million or 61.3% to RMB 12.8 million as of December 31, 2024, due to a reduction in raw material purchases[72] - The gearing ratio improved to approximately 18.7% as of December 31, 2024, down from 22.0% in 2023[79] - Capital expenditure for the year was approximately RMB 7.4 million, significantly higher than RMB 1.7 million in 2023, indicating increased investment in property, plant, and equipment[80] - The Group did not have any outstanding borrowings or pledges of assets as of December 31, 2024[78] - Revenue from the Group's five largest customers accounted for less than 30% of total revenue, with the largest customer contributing less than 10%[174]